Cardiac and vascular serious adverse events following tixagevimab-cilgavimab - Author's reply.

Maselkar, Sheetal; Kiazand, Alexandre; Templeton, Alison; Montgomery, Hugh; Esser, Mark T

Maselkar, Sheetal; Kiazand, Alexandre; Templeton, Alison; Montgomery, Hugh; Esser, Mark T.

Maselkar S; Patient Safety, Chief Medical Office, R&D, AstraZeneca, Gaithersburg, MD 20878-2204, USA.
Kiazand A; Patient Safety, Chief Medical Office, R&D, AstraZeneca, Gaithersburg, MD 20878-2204, USA.
Templeton A; Biometrics, Vaccines and Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
Montgomery H; Department of Medicine, University College London, London, UK.
Esser MT; Vaccines and Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD 20878-2204, USA. Electronic address: mark.esser@astrazeneca.com.

Lancet Respir Med ; 11(1): e7-e8, 2023 01.

Article in English | MEDLINE | ID: covidwho-2170709

Subject(s)

Antibodies, Monoclonal; Humans

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antibodies, Monoclonal Limits: Humans Language: English Journal: Lancet Respir Med Year: 2023 Document Type: Article Affiliation country: S2213-2600(22)00450-7

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google